3PO is originally reported to inhibit PFKFB3 (IC50 = 25 μM). More recent reports failed to demonstrate activity in a PFKFB3 kinase assay. Reduces glycolytic flux and suppresses glucose uptake. Inhibits endothelial cell proliferation and causes G2/M cell cycle arrest in vitro. Attenuates vessel sprouting and tumor growth in vivo. Amplifies the antiangiogenic effect of VEGFR blockade.
Technical Data for 3PO
Formula
C13H10N2O
Storage
Store at -20°C
Purity
≥99%
CAS Number
13309-08-5
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility for 3PO
Solubility
Soluble Soluble to 100 mM in DMSO
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Reconstitution Calculator
References for 3PO
References are publications that support the biological activity of the
product.
Bio-Techne uses cookies to provide you with a great website experience. By continuing to use this website you acknowledge this and agree to our cookie policy. Learn more.